A clinical interpretation of 2009 EASL guidelines on chronic hepatitis B treatment / 中国实用内科杂志

ABSTRACT

With the availality of new nucleotides (acid) analogues,the experience of anti-virus treatment has been continuously enriched.However,the problem of drug resistance becomes increasingly significant and the concern of individualized strategies,duration and endpoints of therapy as well as drug-resistance prevention for nucleoside (acid) analogues treatment has become a hot issue.Thus,the European Association for the Study of the Liver updated their guideline on diagnosis and treatment of chronic hepatitis B based on the principles of evidence-based medicine,so as to make it more flexible and practical.We briefly review and compare the updated content of this new guideline,and make analysis combined with the clinical practice,so as to promote the standardization of diagnosis and treatment of chronic hepatitis B.